middle.news
Starpharma brings DEP HER2-Lu closer to first patient dosing
10:05am on Thursday 22nd of October, 2026 AEDT
•
Biotechnology
Read Story
Starpharma brings DEP HER2-Lu closer to first patient dosing
10:05am on Thursday 22nd of October, 2026 AEDT
Key Points
European CTA submitted for DEP HER2-Lu Phase 1 study
Clinical material manufacture completed ahead of first-in-human testing
Starpharma increased Petalion stake from 22.5% to 66%
AUD $32 million entitlement offer completed in August
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE